Evidence map›Paper›PMID 41296234›Full record

ArticleInfectious diseases and therapy2026

Growth in Anaerobic Bottles is an Independent Predictor of Mortality in Pseudomonas aeruginosa Bloodstream Infections.

Daniel N Marco, Laura Morata, Cristina Pitart, Marta Bodro, Ana Del Río, Carolina Garcia-Vidal, Diego Duminy-Luppi, José Canela, Maria Brey, Marta Hernández-Meneses and 8 more

Abstract read
In one paragraph

Article in Infectious diseases and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Daniel N MarcoDepartment of Infectious Diseases, Hospital Clínic of Barcelona, 170 Villarroel Street, 08036, Barcelona, Spain.
Laura MorataDepartment of Infectious Diseases, Hospital Clínic of Barcelona, 170 Villarroel Street, 08036, Barcelona, Spain.
Cristina PitartFaculty of Medicine, University of Barcelona, Barcelona, Spain.
Marta BodroDepartment of Infectious Diseases, Hospital Clínic of Barcelona, 170 Villarroel Street, 08036, Barcelona, Spain.
Ana Del RíoDepartment of Infectious Diseases, Hospital Clínic of Barcelona, 170 Villarroel Street, 08036, Barcelona, Spain.
Carolina Garcia-VidalDepartment of Infectious Diseases, Hospital Clínic of Barcelona, 170 Villarroel Street, 08036, Barcelona, Spain.
Diego Duminy-LuppiDepartment of Infectious Diseases, Hospital Clínic of Barcelona, 170 Villarroel Street, 08036, Barcelona, Spain.
José CanelaDepartment of Infectious Diseases, Hospital Clínic of Barcelona, 170 Villarroel Street, 08036, Barcelona, Spain.
Maria BreyDepartment of Infectious Diseases, Hospital Clínic of Barcelona, 170 Villarroel Street, 08036, Barcelona, Spain.
Marta Hernández-MenesesDepartment of Infectious Diseases, Hospital Clínic of Barcelona, 170 Villarroel Street, 08036, Barcelona, Spain.
Guillermo CuervoDepartment of Infectious Diseases, Hospital Clínic of Barcelona, 170 Villarroel Street, 08036, Barcelona, Spain.
Mateu EspasaDepartment of Microbiology, Hospital Clínic, 08036, Barcelona, Spain.
Climent Casals-PascualDepartment of Microbiology, Hospital Clínic, 08036, Barcelona, Spain.
Felipe GarcíaDepartment of Infectious Diseases, Hospital Clínic of Barcelona, 170 Villarroel Street, 08036, Barcelona, Spain.
Josep MensaDepartment of Infectious Diseases, Hospital Clínic of Barcelona, 170 Villarroel Street, 08036, Barcelona, Spain.
José Antonio MartínezDepartment of Infectious Diseases, Hospital Clínic of Barcelona, 170 Villarroel Street, 08036, Barcelona, Spain.
Sabina HerreraDepartment of Infectious Diseases, Hospital Clínic of Barcelona, 170 Villarroel Street, 08036, Barcelona, Spain. sherrera@clinic.cat.ORCID http://orcid.org/0000-0002-5057-354X
Alex SorianoDepartment of Infectious Diseases, Hospital Clínic of Barcelona, 170 Villarroel Street, 08036, Barcelona, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionPseudomonas aeruginosa is a leading cause of bloodstream infections (BSI) in hospitalized patients. Although it is regarded as an aerobic microorganism, under certain conditions it can switch to anaerobic respiration using other terminal electron acceptors other than oxygen. The study aims to evaluate the clinical and microbiological factors associated with P. aeruginosa isolation in anaerobic blood culture bottles and determine whether anaerobic growth is an independent risk factor for septic shock and 30-day mortality in patients with P. aeruginosa BSI.

methodsThis was a retrospective unicentric study analyzing 734 episodes of P. aeruginosa BSI at a university hospital from 2010 to 2019. Clinical presentation, comorbidities, source of infection, microbiologic data, and outcomes were collected. Anaerobic growth was defined as the isolation of P. aeruginosa in at least one anaerobic blood culture bottle. Multivariate logistic regression models were used to identify factors associated with septic shock and 30-day mortality.

resultsP. aeruginosa was isolated in anaerobic bottles in 19.1% of cases, though it was never exclusively isolated in anaerobic bottles. While median time to positivity (TTP) in anaerobic bottles was significantly longer than in aerobic ones (16.5 h vs. 14.8 h, p < 0.01), TTP in aerobic bottles was shorter when P. aeruginosa was also isolated in anaerobic bottles (12.5 h vs. 15.5 h, p < 0.01). Factors significantly associated with anaerobic growth included chronic kidney disease, longer time of admission, active antibiotic treatment, and several sources of bacteremia (catheter-related, respiratory, and primary bacteremia). Anaerobic growth was independently associated with higher odds of septic shock (OR 2.8, p < 0.01) and increased 30-day mortality (OR 2.3, p < 0.01). Moreover, septic shock and mortality rates were higher when P. aeruginosa grew in both anaerobic bottles.

conclusionsAnaerobic growth of P. aeruginosa in blood cultures is an independent predictor of septic shock and 30-day mortality in patients with P. aeruginosa BSI. The potential relationship between higher bacterial load and biofilm formation in the source of infection with anaerobic growth of P. aeruginosa may contribute to the observed poorer outcomes.

Indexed as

Anaerobic growthBloodstream infectionPseudomonas aeruginosa

Identifiers

PMID41296234
PMCPMC12783466

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.